CCL13/MCP-4 Antibody [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 594

CCL13/MCP-4 Antibody [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human CCL13/MCP-4
  Gln24-Thr98
  Accession # Q99616
• Specificity: Detects human CCL13/MCP-4 in direct ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL13/MCP-4 Antibody [Alexa Fluor® 594]

• C-C motif chemokine 13
• CCL13
• chemokine (C-C motif) ligand 13
• CKb10
• MCP4
• MCP-4
• MCP-4Monocyte chemoattractant protein 4
• MGC17134
• NCC-1Monocyte chemotactic protein 4
• NCC1Small-inducible cytokine A13
• new CC chemokine 1
• SCYA13CK-beta-10
• SCYL1
• small inducible cytokine subfamily A (Cys-Cys), member 13

Background

Human CCL13 is a CC chemokine recently cloned from a human fetal and a human heart cDNA library. Human CCL13 cDNA encodes a 98 amino acid residue precursor protein with a 23 amino acid residue hydrophobic signal peptide that is cleaved to yield an 8 kDa, 75 aa mature CCL13. Mature CCL13 lacks any potential N-glycosylation sites and shares a pyroglutamate proline motif with other human MCP proteins. Human CCL13 is most homologous to MCP-1, 3 and Eotaxin, exhibiting approximately 65-66% amino acid sequence identity. CCL13 mRNA is expressed by a number of activated cell types, including endothelial cells, macrophages, bronchial epithelium and type II alveolar cells, and perhaps lymphocytes. CCL13 is a chemoattractant for monocytes and eosinophils, and activates basophils. In addition, it has been reported to be chemotactic for CD4⁺ and CD8⁺ T cells, with an activity almost equivalent to that of MCP-3. The bioactivities of CCL13 is most likely mediated by the CC chemokine receptors CCR-2 and CCR-3, both of which have been shown to bind CCL13.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.